Fox Chase Cancer Center News

PHILADELPHIA (February 21, 2014) – Accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) signifies excellence in all quality aspects of patient care and collection practices related to cellular therapy treatments.

PHILADELPHIA, PA (February 20, 2014)—In the cells of humans and other organisms, only a subset of genes are active at any given time, depending largely on the stage of life and the particular duties of the cell. Cells use different molecular mechanisms to orchestrate the activation and deactivation of genes as needed. One central mechanism is an intricate DNA packaging system that either shields genes from activation or exposes them for use.

Proceeds from the carnival-inspired event will go toward research at Fox Chase

DOYLESTOWN, PA (February 4, 2014)—The Bucks County Chapter of Fox Chase Cancer Center’s Board of Associates will celebrate the excitement of Rio de Janeiro’s Carnival with the event “April in Rio” to be held on Saturday, April 12, 2014 from 6:30 to 10:30 p.m., at the James A. Michener Art Museum (138 South Pine Street in Doylestown, PA).  All money raised at the event will benefit research at Fox Chase Cancer Center.

PHILADELPHIA, PA (January 15, 2014) In his new roles, Beck will oversee all activities that support the academic and research operations of Fox Chase.

PHILADELPHIA, PA (January 7, 2014)  Fung will serve as Clinical Leader of the Blood Cancers Program and the Hematologic Oncology Service Line, and Professor of Medical Oncology. He will also be Director of the Temple University Hospital Bone Marrow Transplant Program.

PHILADELPHIA (January 7, 2014) – Larry R. Kaiser, MD, FACS, Dean of Temple University School of Medicine and President/CEO of Temple University Health System, of which Fox Chase is a part, has been appointed to the Governing Council of the American Hospital Association's Constituency Section for Health Care Systems. Appointed leaders represent premier health systems throughout the country.

PHILADELPHIA (December 12, 2013)—Researchers at Fox Chase Cancer Center are enrolling newly diagnosed breast cancer patients into a clinical trial of the promising drug reparixin, which targets tumors' ability to self-renew. The study, being presented at the 2013 San Antonio Breast Cancer Symposium, comes on the heels of research done in a Phase Ib pilot trial in which patients with metastatic disease take reparixin along with the chemotherapy drug paclitaxel (brand name Taxol), designed to assess the safety of dosage.

PHILADELPHIA (November 22, 2013)—Fox Chase Cancer Center, the first acute care hospital in Pennsylvania and specialty hospital in the country to receive Magnet designation for excellence in nursing services by the American Nurses Credentialing Center's (ANCC) Magnet Recognition Program®, has been designated with this prestigious recognition for the fourth time in a row—now making it the first hospital in Pennsylvania to have achieved three successful re-designations.